Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,270.44
(
-1.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 89977

Friday, 08/20/2010 6:10:58 AM

Friday, August 20, 2010 6:10:58 AM

Post# of 257580
Sigmapharm Laboratories files Paragraph-IV challenge for GILD’s Hepsera:

http://finance.yahoo.com/news/Gilead-Sciences-Announces-bw-974569144.html?x=0&.v=1

The obvious question is: Why bother? For all practical purposes, Hepsera has been superseded by Viread. Even if Sigmapharm prevails in the patent litigation, by the time the 30-month Hatch-Waxman stay expires, US Hepsera sales will not amount to much.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today